博瑞医药(688166.SH)：依维莫司原料药获欧洲CEP证书

智通财经02-19

智通财经APP讯，博瑞医药(688166.SH)发布公告，公司的依维莫司原料药收到了欧洲药品质量管理局签发的CEP(欧洲药典适用性认证)证书。依维莫司适用于既往接受舒尼替尼或索拉非尼治疗失败的晚期肾细胞癌成人患者;不可切除的、局部晚期或转移性的、分化良好的(中度分化或高度分化)进展期胰腺神经内分泌瘤成人患者;无法手术切除的、局部晚期或转移性的、分化良好的、进展期非功能性胃肠道或肺源神经内分泌肿瘤(...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2412590303?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-02-19 15:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2412590303","market":"sh","top_or_hot":-1,"title":"博瑞医药(688166.SH)：依维莫司原料药获欧洲CEP证书","media":"智通财经","content":"<div>\n<p>智通财经APP讯，博瑞医药(688166.SH)发布公告，公司的依维莫司原料药收到了欧洲药品质量管理局签发的CEP(欧洲药典适用性认证)证书。依维莫司适用于既往接受舒尼替尼或索拉非尼治疗失败的晚期肾细胞癌成人患者;不可切除的、局部晚期或转移性的、分化良好的(中度分化或高度分化)进展期胰腺神经内分泌瘤成人患者;无法手术切除的、局部晚期或转移性的、分化良好的、进展期非功能性胃肠道或肺源神经内分泌肿瘤(...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1073022.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>博瑞医药(688166.SH)：依维莫司原料药获欧洲CEP证书</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n博瑞医药(688166.SH)：依维莫司原料药获欧洲CEP证书\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-02-19 15:40 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1073022.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，博瑞医药(688166.SH)发布公告，公司的依维莫司原料药收到了欧洲药品质量管理局签发的CEP(欧洲药典适用性认证)证书。依维莫司适用于既往接受舒尼替尼或索拉非尼治疗失败的晚期肾细胞癌成人患者;不可切除的、局部晚期或转移性的、分化良好的(中度分化或高度分化)进展期胰腺神经内分泌瘤成人患者;无法手术切除的、局部晚期或转移性的、分化良好的、进展期非功能性胃肠道或肺源神经内分泌肿瘤(...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1073022.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2286300806.USD","symbol_name":"Allianz Cyber Security AT Acc USD","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1073022.html","article_id":"2412590303","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2412590303","pubTimestamp":1708328427,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，博瑞医药 发布公告，公司的依维莫司原料药收到了欧洲药品质量管理局签发的CEP证书。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2286300806.USD":"Allianz Cyber Security AT Acc USD","BK4585":"ETF&股票定投概念","BK4116":"互联网服务与基础架构","BK4560":"网络安全概念","BK4554":"元宇宙及AR概念","BK4548":"巴美列捷福持仓","NET":"Cloudflare, Inc."},"translate_title":"Borui Medicine (688166. SH): Everolimus API has obtained European CEP certificate","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NET":1},"content_text":"智通财经APP讯，博瑞医药(688166.SH)发布公告，公司的依维莫司原料药收到了欧洲药品质量管理局签发的CEP(欧洲药典适用性认证)证书。依维莫司适用于既往接受舒尼替尼或索拉非尼治疗失败的晚期肾细胞癌成人患者;不可切除的、局部晚期或转移性的、分化良好的(中度分化或高度分化)进展期胰腺神经内分泌瘤成人患者;无法手术切除的、局部晚期或转移性的、分化良好的、进展期非功能性胃肠道或肺源神经内分泌肿瘤(NET)成人患者;需要治疗干预但不适于手术切除的结节性硬化症(TSC)相关的室管膜下巨细胞星形细胞瘤(SEGA)成人和儿童患者;不需立即手术治疗的结节性硬化症相关的肾血管平滑肌脂肪瘤(TSC-AML)成人患者。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2412590303"}